New transplant regimen aims to boost survival for blood cancer patients
NCT ID NCT07214688
Summary
This study is testing a new combination of chemotherapy drugs and radiation given before a stem cell transplant. The goal is to see if this approach improves one-year survival for adults aged 18-65 with certain blood cancers like leukemia or lymphoma. After the transplant, patients will take medications to prevent complications and manage their immune system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC STEM CELL TRANSPLANT RECIPIENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Center at Jersey Shore University Medical Center
NOT_YET_RECRUITINGNeptune City, New Jersey, 07753, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Conditions
Explore the condition pages connected to this study.